๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lung Cancer
Clinical trial register · China

Lung Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 38 Shanghai 34 Beijing 24 Chengdu 13 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University10 Shanghai Chest Hospital9 Shanghai Pulmonary Hospital, Shanghai, China8 The First Affiliated Hospital of Guangzhou Medical University6 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology5
Site location
Guangzhou38 Shanghai34 Beijing24 Chengdu13 Wuhan11
All 49 locations
Target enrolment
to

Lung Cancer trials in China

134 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Antigen-specific T Cells Against Lung Cancer
NCT03356808Lung Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-06-01
Not yet open
5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies
NCT07830095Lung Cancer
Shanghai Chest Hospital
Not applicable
15
Shanghai
2026-09-30
Not yet open
AI-Assisted Chest CT Interpretation Across the Lung Cancer Care Continuum
NCT07829640Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
15
Wuhan
2026-09
Recruiting
TROP2 NMR Concordance Study
NCT07624318Lung Cancer
AstraZeneca
Observational
3,400
Beijing, Guangzhou, Shanghai
2026-08-13
Recruiting
Precision Navigation to Improve Community Cancer Screening Participation
NCT07676383Cancer Screening, Lung Cancer, Breast Cancer, Colorectal Cancer
Hunan Cancer Hospital
Not applicable
1,500
Huaihua, Shaoyang, Yongzhou
2026-08-04
Recruiting
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
NCT07760012Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
Peking University Third Hospital
Not applicable
50
Beijing
2026-07-24
Recruiting
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
NCT07681245Lung Cancer
Shanghai Chest Hospital
Observational
294
Shanghai
2026-07-03
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
NCT07645222Lung Cancer
Hansoh BioMedical R&D Company
Phase 1
396
Guangzhou
2026-06-15
Not yet open
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NCT07589101Lung Cancer, Breast Cancer
Peking University Cancer Hospital & Institute
Not applicable
20
Beijing
2026-06-01
Recruiting
Association Between Screening Behaviors and Lung Cancer Spectrum
NCT07626177Lung Cancer
Fudan University
Observational
5,390
Shanghai
2026-05-14
Not yet open
A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors
NCT07014878Colorectal Cancer, Lung Cancer, Pancreatic Cancer
Beijing DCTY Biotech Co.,Ltd.
Phase 1
18
Shanghai
2026-05
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Recruiting
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
NCT07552467Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
26
Wuhan
2026-04-01
Not yet open
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
NCT07538973Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
24
Xiamen, Zhengzhou, Qingdao
2026-04
Not yet open
Video Double-Lumen Tube for Secondary Pulmonary Resection
NCT07467005Lung Cancer, Pulmonary Nodule
Zhejiang University
Not applicable
500
Hangzhou, Yiwu
2026-03-16
Recruiting
Olive Oil Before Lung Cancer Surgery to Prevent Chylothorax
NCT07807696Lung Cancer, Chylothorax
Fudan University
Not applicable
1,036
Shanghai
2026-03-15
Recruiting
Prospective Phase II Clinical Study of Stereotactic Body Proton Therapy (SBPT) for Lung Cancer
NCT07412327Early-Stage Lung Cancer, Lung Cancer
Guangzhou Concord Cancer Center
Not applicable
65
Guangzhou
2026-02-24
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Not yet open
Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions
NCT07352176Pulmonary Lesion, Lung Cancer
Guangzhou Medical University
Not applicable
40
Guangzhou
2026-02-01
Recruiting
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
NCT07354711Lung Cancer, Stomach Cancer
3H Pharmaceuticals Co., Ltd.
Phase 1/2
170
Beijing
2026-01-04
Recruiting
Large Language Models Assist in Tumor MDT
NCT07504367Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
60
Guangzhou
2026-01-01
Recruiting
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07274852Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Chengdu
2025-12-10
Recruiting
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT07232849Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
100
Shanghai, Hangzhou
2025-12-04
Recruiting
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
NCT07243873Lung Cancer, PET-CT
Shanghai Pulmonary Hospital, Shanghai, China
Observational
10,000
Zunyi, Jiangxi, Shanghai, Ningbo
2025-12-01
Not yet open
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT07244926Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
31
Tianjin
2025-12
Recruiting
Safety and Efficacy Evaluation of Cryoablation in the Treatment of Ground-Glass Nodules
NCT07232433Lung Cancer
Ruijin Hospital
Not applicable
90
Shanghai
2025-11-21
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
NCT07241767Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-11-12
Recruiting
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
NCT07617246Esophagus Cancer, Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
120
Hangzhou
2025-11-01
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
VSV-02 Compassionate Use in Advanced Solid Tumors
NCT07260591Advanced Solid Tumor, Melanoma, Breast Cancer, Lung Cancer
The First Affiliated Hospital of Xinxiang Medical College
Phase 1
6
Xinxiang
2025-09-22
Recruiting
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
NCT07179692Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
108
Hefei
2025-09-12
Active, closed
Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules
NCT07638228Malignant Pulmonary Nodules, Lung Cancer
Sir Run Run Shaw Hospital
Not applicable
5
Hangzhou
2025-09-01
Recruiting
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
NCT06232083Lung Cancer, Esophageal Cancer, Cervical Cancer
Anhui Provincial Hospital
Phase 1
20
Hefei
2025-09-01
Recruiting
Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
NCT07134660Postoperative Pain, Acute, Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
210
Shanghai
2025-09-01
Recruiting
Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT07135856Lung Cancer, Neoadjuvant Therapy
Shanghai Chest Hospital
Observational
400
Shanghai
2025-09-01
Not yet open
A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
NCT07101627Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
149
Nanjing, Shanghai
2025-08-01
By invitation
Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?
NCT07494006Lung Cancer, OLV, Hypoxemia During Surgery
Peking University People's Hospital
Observational
44
Beijing
2025-07-15
Recruiting
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage โ…กA-โ…ขB Non-small Cell Lung Cancer
NCT06877299Lung Cancer, Non-small Cell Lung Cancer
Sichuan University
Phase 2
30
Chengdu
2025-07-04
Recruiting
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Beijing, Cangzhou, Tianjin
2025-07-01
Recruiting
Transbronchial MWA for Pulmonary Tumors
NCT06969014Lung Cancer
Shanghai Chest Hospital
Not applicable
15
Shanghai
2025-05-12
Not yet open
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors
NCT06948539Breast Cancer, Lung Cancer, Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
66
Guanzhou
2025-04
Not yet open
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
NCT06688656Lung Cancer
Shanghai Chest Hospital
Phase 2
30
Shanghai
2025-03-31
Recruiting
Organoid-guided Personalized Treatment of Pleural Effusion
NCT06959173Lung Cancer
Henan Cancer Hospital
Observational
20
Zhengzhou
2025-02-21
Recruiting
Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
NCT06818149Lung Cancer, Myocarditis Due to Drug
Shanghai Chest Hospital
Observational
50
Shanghai
2025-01-30
Not yet open
The Impact of Thoracic Paravertebral Nerve Block At Different Positions on Pain Relief in Patients Undergoing Single-Port Thoracoscopic Partial Lung Resection
NCT06789276Lung Nodules, Lung Cancer
Second Affiliated Hospital of Soochow University
Not applicable
200
Suzhou
2025-01-18
Recruiting
Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy
NCT06776588Lung Cancer
Beidahuang Industry Group General Hospital
Not applicable
200
Harbin
2025-01-15
Recruiting
The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
NCT06692972Lung Cancer
China-Japan Friendship Hospital
Observational
500
Beijing, Wuhan
2024-12-25
Recruiting
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
NCT07026110Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
RenJi Hospital
Not applicable
100
Shanghai
2024-12-23
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
NCT06749886Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
22
Shanghai
2024-11-19
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Recruiting
Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
NCT06742021Lung Cancer
Yunnan Cancer Hospital
Not applicable
195
Kunming
2024-11-11
Recruiting
The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
NCT06975384Lung Cancer, Sleep Disturbance, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
Second Xiangya Hospital of Central South University
Observational
1,270
Changsha
2024-11-01
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
Sun Yat-sen University
Observational
470
Beijing
2024-10-04
Recruiting
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
NCT06572540Lung Cancer
Jiayuan Sun
Not applicable
110
Guangzhou, Zhengzhou, Shanghai, Chengdu, Hangzhou
2024-09-01
Recruiting
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
NCT06607770Lung Cancer
Zhou Chengzhi
Phase 1/2
20
Guangzhou
2024-09-01
Recruiting
Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.
NCT06458894Lung Cancer
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Not applicable
100
Yiwu
2024-08-24
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
Essen Biotech
Phase 1/2
85
Beijing
2024-08-20
Recruiting
A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging
NCT07463300Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
5,500
Guangzhou, Wuhan, Yangzhou, Shenyang, Chengdu, Hangzhou
2024-08-01
Recruiting
Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach๏ผˆRadiogenomics-Lung๏ผ‰
NCT06500312Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
150
Wuhan
2024-07-02
Recruiting
The Impact of AI Assistance on Radiologist Performance and Healthcare Costs in LDCT-Based Lung Cancer Screening
NCT06988579Lung Cancer, Artificial Intelligence (AI), Randomized Controlled Trial
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
7,294
Guangzhou
2024-07-01
Recruiting
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
NCT06492421Lung Cancer, Surgery, Non-small Cell Lung Cancer
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guanzhou
2024-07-01
Recruiting
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
NCT06528418Lung Cancer, Lung Infection, COPD, Bronchitis
ChromX Health
Observational
10,000
Guangzhou
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Not yet open
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
NCT06453889Lung Cancer
Shanghai Chest Hospital
Not applicable
10
Shanghai
2024-06-05
Recruiting
Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
NCT07131670Lung Cancer, Chemoradiotherapy, Patient-Reported Outcomes (PRO)
Qian Chu
Observational
100
Wuhan
2024-06-01
Recruiting
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
NCT06421298Lung Cancer
Jinghui Wang
Phase 2
30
Beijing
2024-05-17
Recruiting
GPC3/Mesothelin-CAR-ฮณฮดT Cells Against Cancers
NCT06196294Pancreas Cancer, Lung Cancer, Liver Cancer, Mesothelioma
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2024-05-10
Recruiting
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
NCT06644066Lung Cancer
Tang-Du Hospital
Not applicable
60
Xi'an
2024-05-01
Active, closed
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
NCT06194448Lung Cancer
AstraZeneca
Phase 2
76
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanning
2024-04-21
Recruiting
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
NCT06217757Lung Cancer, Extensive-stage Small-cell Lung Cancer
Sichuan University
Phase 1/2
45
Chengdu
2024-04-18
Recruiting
Effect of Transcutaneous Acupoint Electrical Stimulation (TAES) on Postoperative Cough in Lung Cancer
NCT06548711Postoperative Cough, Lung Cancer
Kong Fanming
Not applicable
84
Tianjin
2024-04-17
Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
NCT06483347Lung Cancer, Inoperable Disease
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
90
Guangzhou
2024-04-04
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
NCT06478108Lung Cancer, Liver Cancer, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3
60
Guangzhou
2024-04-01
Recruiting
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
NCT06383728Lung Cancer, Carcinoma, Squamous Cell
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
51
Guangzhou
2024-04-01
Recruiting
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
NCT06483295Lung Cancer
Shanghai Chest Hospital
Not applicable
216
Shanghai
2024-03-24
Active, closed
A Trial to Compare Robotic Assisted Bronchoscopy Ion's Clinical Utility for Peripheral Lung Nodule Access and Diagnosis to ENB
NCT06308120Pulmonary Nodule, Solitary, Lung Cancer
Intuitive Surgical
Not applicable
354
Shanghai, Chengdu
2024-03-20
Recruiting
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
NCT06244264Spinal Metastases, Blood Transfusion Complication, Lung Cancer, Surgery
Guangdong Provincial People's Hospital
Not applicable
118
Guangzhou
2024-03-15
Recruiting
Risk Factors for Postoperative Cough in Patients Undergoing Thoracoscopic Lung Resection
NCT06476249Lung Cancer
Hematology department of the 920th hospital
Observational
1,000
Kunming
2024-03-01
Recruiting
Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery
NCT06483698Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
20,000
Beijing
2024-03-01
Recruiting
Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy
NCT06607796Lung Cancer
Zhou Chengzhi
Phase 3
180
Guangzhou
2024-03-01
Recruiting
Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
NCT06749860Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
58
Shanghai
2024-02-02
Recruiting
Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients
NCT06215326Lung Cancer
Guangdong Provincial People's Hospital
Not applicable
100
Guangzhou
2024-01-23
Recruiting
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.
NCT06843707Lung Cancer, Lung, Lung Cancer (NSCLC), Metabolomics
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2024-01-01
Recruiting
Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study
NCT06216782Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-12-16
Recruiting
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
NCT06168032COVID-19 Recurrent, Lung Cancer, Vaccination, Antibody
Peking Union Medical College Hospital
Not applicable
1,224
Beijing
2023-12-08
Recruiting
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
NCT06199895Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer
Liu Huang
Phase 2
25
Wuhan
2023-11-28
Recruiting
Assessment System of Sarcopenia in Lung Cancer Patients
NCT06327594Sarcopenia, Lung Cancer, Ultrasound
West China Hospital
Observational
1,500
Chengdu
2023-11-01
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
NCT06399926Leptomeningeal Metastasis, Lung Cancer
Xiangya Hospital of Central South University
Observational
64
Changsha
2023-10-30
Recruiting
DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs
NCT06329908Lung Cancer
Zhen-Yu Ding
Phase EARLY_PHASE1
20
Chengdu
2023-09-27
Recruiting
Efficacy and Safety of Single-port Surgical Robot System in Thoraic Surgery
NCT06286150Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
20
Guangzhou
2023-09-15
Recruiting
Exploratory Study of Precise Therapy for Advanced Tumor Patients With Malignant Hydrothorax or Ascites by Using PTC Drug Sensitivity Testing
NCT06413212Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer
Liu Huang
Observational
55
Wuhan
2023-08-04
Recruiting
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
NCT05754203Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy
Xinqiao Hospital of Chongqing
Not applicable
40
Chongqing
2023-08-01
Recruiting
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT05965557Lung Cancer
Geneplus-Beijing Co. Ltd.
Observational
100
Shanghai
2023-06-19
Recruiting
Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
NCT05857800Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
2,000
Shanghai
2023-05-25
Recruiting
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
NCT05886439Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
60
Beijing
2023-05-11
Recruiting
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
NCT05834413Lung Cancer
Shanghai University of Traditional Chinese Medicine
Not applicable
367
Shanghai
2023-05-01
Rows per page Showing 1–100 of 134
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/lung-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 134 of those studies listing the condition Lung Cancer.

How many Lung Cancer trials are recruiting in China?

104 of the 134 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 16 have not yet opened recruitment, 13 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lung Cancer), 134 studies
PhaseStudiesRecruitingShare
Observational474235.1%
Not applicable362726.9%
Phase 2201314.9%
Phase 113109.7%
Phase 1/2976.7%
Phase 3624.5%
Phase 2/3221.5%
Phase EARLY_PHASE1110.7%

Most active sponsors

Lead sponsors with the most studies (Lung Cancer)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Guangzhou Medical University1010
Shanghai Chest Hospital96
Shanghai Pulmonary Hospital, Shanghai, China86
The First Affiliated Hospital of Guangzhou Medical University66
AstraZeneca53
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology54
Cancer Institute and Hospital, Chinese Academy of Medical Sciences33
Fudan University32
Guangdong Provincial People's Hospital33
Second Affiliated Hospital, Zhejiang University, School of Medicine32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.